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Abstract: A library of mannose- and fucose-based glycomi-
metics was synthesized and screened in a microarray format
against a set of C-type lectin receptors (CLRs) that included
DC-SIGN, DC-SIGNR, langerin, and dectin-2. Glycomimetic li-
gands able to interact with dectin-2 were identified for the
first time. Comparative analysis of binding profiles allowed
their selectivity against other CLRs to be probed.
Introduction
Lectins are sugar-binding proteins that engage in interactions
with endogenous and exogenous glycans. The interactions be-
tween lectins and carbohydrates are involved in many funda-
mental biological events, from cell adhesion to antigen recog-
nition and internalization, inflammation, or quality control in
protein folding. The most abundant class of animal lectins are
the C-type lectin receptors (CLRs) serving a broad range of
functions. They are involved in pathogen recognition and in
prevention of autoimmunity by contributing to the immune
system’s ability to identify carbohydrate-based pathogen-asso-
ciated molecular patterns (PAMP) and damaged-self-associated
molecular patterns (DAMP).They take part in signal transduc-
tion, cell trafficking, and in the induction of T-cell differentia-
tion. Their name, C-type lectins, indicates the presence of a
Ca2+ ion in their carbohydrate recognition domain (CRD). This
ion is the primary site of carbohydrate interaction and typically
coordinates two vicinal hydroxyl groups on a sugar ring. Many
C-type lectin receptors are yet to be explored and described in
detail with regard to their CRD structure, carbohydrate binding
specificities, and the molecular factors governing the interac-
tion with glycans. However, it is known that the CRDs of CLRs
feature evolutionarily conserved groups of residues that coor-
dinate the Ca2+ ion and determine the monosaccharide bind-
ing specificity of the CLR. So, a Glu-Pro-Asn (EPN) motif results
in a preference for mannose (Man), N-acetylglucosamine
(GlcNAc), fucose (Fuc), or glucose (Glc) residues, whereas a
Gln-Pro-Asp (QPD) sequence leads to recognition of galactose
(Gal) and N-acetylgalactosamine (GalNAc).[1] Available data also
suggests that the extended binding sites of CLRs often display
a higher affinity towards larger glycan structures, thanks to ad-
ditional interactions occurring in the vicinity of the primary
Ca2+ site.[2] Thus, complex glycans exposing the same mono-
saccharide can bind to CLRs with very different affinities, de-
pending on the accessibility of the recognition element and
on additional features of the lectin binding sites. Structural
studies also demonstrate that secondary binding sites can alter
the affinity and specificity of the CLR towards ligands. As an
example, langerin,[3] a transmembrane CLR expressed on Lan-
gerhans-cells, and the dendritic-cell specific intercellular adhe-
sion molecule-3-grabbing non-integrin (DC-SIGN), a CLR ex-
pressed by dendritic cells (DCs)[4] share similar primary binding
sites with similar specificity for oligomannosides, but langerin
has an additional calcium-independent sugar-binding site and
binds to large sulfated glycosamino glycans, whereas DC-SIGN
does not.[5]
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Given the key role played by lectins in biological systems,
many research groups have turned their attention towards the
development of glycomimetic molecules to be used as selec-
tive probes for the study of sugar–protein interactions and/or
for medicinal chemistry purposes.[6] Glycomimetics present sev-
eral advantages as drug candidates over natural glycans, since
they can be made metabolically more stable, more bioavail-
able, and possibly more active and selective than natural oligo-
saccharides. Our previous studies have focused on inhibiting
the dendritic cell receptor DC-SIGN, a CLR implicated in viral
and bacterial infections.[7] The primary binding site of DC-SIGN
CRD recognizes mannose oligosaccharides, l-fucose residues in
Lewis-type blood antigens,[4] and biantennary N-glycans with
terminal GlcNAc moieties.[8] Additional druggable sites on the
lectin have been described recently.[9] DC-SIGN-mediated adhe-
sion to dendritic cells is the first step of several viral infections,
notably by HIV and Ebola viruses.[10] Glycomimetic antagonists
of DC-SIGN have mainly been designed starting from high
mannose glycans, like Man9 (Man)9(GlcNAc)2 (1, Figure 1), or
from LeX (Fuca1,3-(Galb1,4-)-GlcNAc) (2)-type structures. In par-
ticular, pseudo-di and tri-mannoside fragments (3–6) were syn-
thesized[11] as mimics of the D2 and D3 arms of Man9
(Figure 1). When used in multivalent constructs, they were
found to block DC-SIGN-mediated infection with activities up
to the nanomolar level both in HIV and Ebola infection
models.[12] Notably, the bisbenzylamide derivatives 6a[11c] and
6b[11d] also exhibited strong selectivity towards DC-SIGN and
did not bind to langerin, a CLR that shares with DC-SIGN a sim-
ilar set of ligands but, rather than spreading the infection, facil-
itates HIV eradication.[13]These results suggested that, with ap-
propriate modifications, the structure of 6 could represent a
general template to generate a diverse library of glycomimet-
ics containing one natural monosaccharide as the lectin-target-
ing element and a tuning unit, which could provide additional
functional elements for interaction with the lectin in the prox-
imity of the primary binding site. As mentioned above, the
structure of 6 derives from mimicry of the Mana1-2Man disac-
charide, the terminal unit of the D1–D3 arms of Man9 and a
common disaccharide ligand for DC-SIGN (PDB: 2IT6) and for
other CLRs of the immune system with similar specificity, such
as DC-SIGNR,[14] langerin (PDB: 3P5F),[15] and dectin-2 (PDB:
5VYB).[16] Screening such a library against these CLRs in a mi-
croarray format may become a potent tool for glycomimetic
drug discovery.[17] Glycan microarrays, as introduced and devel-
oped over the past 15 years, have been an essential tool in the
characterization of lectin specificity,[18] and have been used to
pave the way for the therapeutic exploitation of vital lectin–
sugar interactions.
Herein, we describe the synthesis of a mannose- and fucose-
based glycomimetic library and its on-chip screening against a
set of human CLRs that led to the discovery of hit ligands able
to interact with dectin-2.[16]
Figure 1. Natural DC-SIGN ligands: Man9 (1)–the D1–D3 arms are the template for the design of mimics 3–6 ; l-Fuc containing Le
X blood group antigen (2).
Linear fragment mimics of Man9 arms: pseudo-mannobioside (3) and pseudo-mannotrioside (4) ; the pseudo-thiomannobioside (5) and two derivatives of
pseudo-mannobioside (6).
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Results and Discussion
Design and synthesis of the library
The set of bis(benzylamide) compounds previously designed
as DC-SIGN antagonists was directly expanded into a man-
nose-based library by adopting the described route[11c] that
starts from diacid 7, with small modifications (Scheme 1).
Scale-up to a multigram scale of the protected common scaf-
fold 11, equipped with a versatile azido-functionality, allowed
further derivatization to a collection of bisamides 12. The gly-
comimetic library was not conceived to specifically target one
lectin, but rather to broadly interact with CLRs that contain the
EPN motif in their CRD. Therefore, the required set of amines
was selected for diversity, with the help of chemoinformatic
tools and based on commercial availability. Lead-like physico-
chemical filters were applied to a large number of amines from
available commercial collections (see the Experimental Section)
and the selection was sifted to exclude any structural incom-
patibility. The remaining structures were then clustered by che-
moinformatic descriptors and representatives of the various
subgroups were selected based on their availability. Overall, a
collection of 38 diverse amines were selected (Figure 2), which
allowed us to prepare the Man-based derivatives 12.1–39
(Scheme 1, Figure 2).
As discussed previously, Man-binding CLRs are expected to
recognize l-Fuc residues as well, due to the overlapping carbo-
hydrate-specificity imparted by the EPN motif. Therefore, in
analogy to the mannobioside mimics, b-fucosylated ligands 15
were synthesized by linking the cyclohexane acceptor (9) with
an appropriately protected fucose-trichloroacetimidate donor
(13) to yield the bis-p-nitrophenylester 14, which was reacted
with a set of primary and secondary amines. This approach af-
forded the 11 Fuc-based ligands 15.1–11 (Scheme 1, Figure 2).
Ligand immobilization on the microarray surface
Although the azidoethyl functionalized glycomimetics could, in
principle, be immobilized directly by surface-based cycloaddi-
tion,[19] we chose to extend the short linker with an additional
hetero-bi-functional spacer prior to printing the library, to im-
prove ligand accessibility. This set-up presents the additional
advantage of allowing the glycomimetics to be printed along-
side existing glycan libraries, which are typically functionalized
with aminoterminated linkers.[20] To this end, commercially
available N-{(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethyloxycar-
bonyl}-1,8-diamino-3,6-dioxaoctane (16, Scheme 2) was submit-
ted to selective, rapid, and bioorthogonal strain-promoted
azide–alkyne cycloaddition (SPAAC), as described by Agard
et al.[21] yielding conjugates 17 and 18 (Figure 2). The azido-ter-
minated ligands reacted quantitatively overnight with 16 and
the reaction products were analyzed by MALDI-TOF-MS to
assess the identity of the resulting compounds, which were
later robotically printed through the terminal amino functional-
ity onto N-hydroxysuccinimidyl ester (NHS)-functionalized glass
slides. To detect any interference of the linker on lectin bind-
ing, compound 19.1 (Figure 2E) was included as a nonglycosy-
lated “clicked-linker”. Conjugation of 2-azidoethyl-d-mannoside
to 16 provided the control mannose glycoside 19.2. In addi-
tion, amines 20 and 21 (Figure 2) were prepared by azide re-
duction of two ligands, 12.1 and 12.2, respectively. The amines
were directly printed on the slides to compare their binding
with the same ligands immobilized through the bifunctional
linker (17.1 and 17.2, respectively).
The final ligand library, conjugated with the additional linker
and printed onto the microarray surface, consisted of 39 a-
mannosylated (17.1–17.39) and 11 b-fucosylated (18.1–18.11)
disaccharide mimics (Figure 2) and included four control com-
pounds (19.1, 19.2, 20, and 21).
Scheme 1. Synthesis and general structure of mannose-(12.1–39) and fucose-derived (15.1–11) members of the glycomimetic library. a) p-Nitrophenyl trifluor-
oacetate, pyridine, DMF, 50 8C, 18 h, 73%; b) mCPBA, CH2Cl2, 16 h, 94%; c) 2-azidoethanol, Cu(OTf)2, CH2Cl2, 70%; d) TMSOTf, @30 8C, 20 min, 74%; e) TMSOTf,
@30 8C, 3.5 h, 74%; f) RR’NH, THF/DMF, (Et3N), 1 h–2 d; g) NaOMe, MeOH, 1.5 h. mCPBA=meta-chloroperbenzoic acid.
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Figure 2. Glycomimetic library of 39 mannosylated, 11 fucosylated, and 4 control compounds. A) General structure of mannose glycomimetics. B) Different R’
substituents present in mannose glycomimetics. C) General structure of fucose glycomimetics. D) Different R’ substituents presented in fucose glycomimetics.
E) Control compounds included in the library.
Scheme 2. Conjugation of azide-containing glycomimetics with cyclooctyne 16 by strain-promoted alkyne–azide cycloaddition (SPAAC).
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After microarray design and optimization of printing param-
eters, the slides were probed with a variety of recombinant
and fluorescently tagged human CLRs, and the binding profile
recorded with a fluorescence scanner. The fluorescence intensi-
ty of individual spots relates to the amount of bound lectin
and is an estimation of the relative strength of interaction. For
a selected set of ligands, the intensity values from the microar-
ray analysis were compared to IC50 values determined in a SPR
competition experiment against DC-SIGN and DC-SIGNR. This
comparison allowed us to critically evaluate the ranking sug-
gested by the array interaction studies and provided a useful
perspective in the screenings performed with other human
CLRs.
Experimental design and data analysis
Glycan microarrays were printed as previously described[8] on
commercially available NHS-ester activated glass slides. The im-
mobilization of the ligands was confirmed by incubation with
fluorescently labeled lectins of known glycan specificity : plant
lectin Concanavalin A (ConA, d-Man)[22] and fungal Aleuria aur-
antia lectin (AAL, l-Fuc).[23] These experiments allowed the op-
timization of the spotting conditions and the validation of the
array. In particular, it was observed that the addition of 10%
DMSO to the printing buffer afforded the most homogeneous
fluorescent images.
On the array, ConA was found to recognize most of the
printed Man-based glycomimetics 17.n as well as the controls
19.2, 20, and 21, whereas no binding to the non-mannosylat-
ed linker 19.1 and to the fucose-based glycomimetics 18.n
was observed (see the Supporting Information, Figure SI-1). In-
terestingly, many of the Man-based mimics appeared to inter-
act with ConA more efficiently than mannose itself (19.2), sup-
porting the hypothesis that secondary interactions can contrib-
ute to the overall affinity of lectin ligands. The intensity of the
signals obtained for 17.1 and 17.2 was somewhat higher than
that of the short-linker controls 20 and 21, which suggests a
better accessibility of the former compounds on the array.
As expected, screening the array with fucose-specific AAL re-
sulted in a totally different interaction profile, involving exclu-
sively the Fuc-based ligands 18.n (see the Supporting Informa-
tion, Figure SI-2). Substitutions to the fucose core apparently
did not affect recognition, as the binding intensity seems
largely the same for all compounds. No binding was observed
to the linker control 19.1 for this or any other of the tested
lectins.
Interaction with human CLRs
DC-SIGN and langerin extracellular domains (ECD) were pro-
duced as previously described.[3a,24] DC-SIGNR ECD and dectin-
2 ECD were expressed in E.coli and purified as detailed in the
Supporting Information. All CLRs were labeled with Cy3 and
the degree of labeling was estimated as described in the Sup-
porting Information.
The analysis was performed under the optimized conditions
described above. Results are reported in Figures 3–5 (see
below), in which ligands are grouped by chemical features
(type of monosaccharide, degree of amide substitution) rather
than by numbering. A comparative heat map for the four pro-
teins is reported in the Supporting Information, Figure SI-3.
DC-SIGN
DC-SIGN is a transmembrane protein expressed primarily on
the surface of dendritic cells in dermal mucosa and on various
other antigen presenting cells of the myeloid lineage. DC-SIGN
has a dual role as a cell surface pattern-recognizing receptor
and as a mediator for T-cell activation. Additionally, a number
of pathogens, most notably the HIV virus, are known to exploit
DC-SIGN in the initial steps of host invasion.[10a,25] For these rea-
sons, DC-SIGN has been actively investigated, both as a target
for discovery of anti-adhesive antiviral therapies and for its po-
tential role in immunoregulation.[26]
The lectin recognizes highly mannosylated oligosaccharides
often found on viral and bacterial cell surfaces; the four Lewis-
type blood group antigens (Lex Ley, Lea, and Leb) and mannan-
capped lipoarabinomannan and phosphatidylinositol-manno-
sides expressed on mycobacterial surfaces.[27] On the array (Fig-
ure 3A), many of the mannosylated structures, but essentially
none of the b-fucosylated ligands are recognized by the tetra-
meric DC-SIGN extracellular domain (ECD). Although DC-SIGN
is known to bind fucosylated oligosaccharides, they all consist
of a-fucosides, whereas, to the best of our knowledge, b-fuco-
sides have not been explored before. The mannose-based li-
gands identified by red bars in Figure 4 had originally been de-
signed as DC-SIGN antagonists and tested by SPR as inhibitors
of DC-SIGN binding to mannosylated BSA.[11c] Both the SPR
data and the microarray results indicate that all these com-
pounds have a similar affinity for the lectin, with the methyl
ester 17.2 being the least effective of the series. None of the
additional modifications of the amide functionality attempted
in this library was found to improve on the previous design.
On the other hand, very low fluorescence intensity was detect-
ed for all tertiary amide derivatives (17.10, 17.20, 17.30, 17.36,
17.37, 17.38, and 17.39) on the chip. This observation con-
firmed early data from previous SPR screenings in our groups,
which had indicated that tertiary amides on the pseudo-di-
mannoside scaffold were significantly reducing the binding af-
finity towards DC-SIGN.[28] The current set of data strongly sug-
gests that this feature can be reliably used to generate selec-
tivity against DC-SIGN. Overall, these data allowed the valida-
tion of microarray results and showed that the screening tech-
nique implemented is robust and adequate for fast analysis of
binding activity.
DC-SIGNR
The DC-SIGN-related homologue, DC-SIGNR (or L-SIGN) is ex-
pressed primarily on sinusoidal endothelial cells in lymph
nodes, the liver, the lungs, the gastrointestinal tract, and capil-
lary endothelial cells in the placenta.[29] The two homologues
exhibit 73% identity at the nucleic acid level and 77% identity
in the amino acid sequences,[30] but display differences in the
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coiled-coil neck domains that affect the spatial arrangement of
the four CRDs. As a result, the two CLRs can show different
avidity towards the same multivalent ligand.[24,31] Similarly to
DC-SIGN, DC-SIGNR is a pathogen receptor for HIV-1, HCV,
SARS-coronavirus and Mycobacterium tuberculosis, recognizes
influenza A and interacts with lymphocytes.[32]
The microarray screening results are shown in Figure 3B.
Many of the mannose-based ligands interact with the protein
more effectively than mannose itself (19.2) and the binding
profile is rather similar to that observed for DC-SIGN. Four li-
gands (17.11, 17.15, 17.19, and 17.27, all shown as blue bars
in Figure 3B) were selected for further analysis and the affinity
of the corresponding recognition elements 12.11, 12.15,
12.19, and 12.27 for DC-SIGN and DC-SIGNR was evaluated
using an SPR inhibition assay that measures their ability to in-
hibit protein binding to mannosylated bovine serum albumin
(Man-BSA) (Figure 3C). The results show some obvious differ-
ences in the way the ligands are classified by the two assays.
In particular, the IC50 value measured by SPR for 12.11 and DC-
SIGN is higher than expected based on the array profile. This
may simply reflect the intrinsic differences of the physical pro-
cesses interrogated in the two assays: in the microarray setup,
direct binding of the tetravalent lectins to a multivalent-func-
tionalized surface is observed; in the SPR inhibition assay, the
ligands are scored based on the strength of their monovalent
interaction with the protein. A strong dependence of the affini-
Figure 3. A) DC-SIGN glycomimetic ligand binding profile at 50 mgmL@1 DC-SIGN ECD (extracellular domain, tetramer). The red bars indicate previously known
DC-SIGN ligands (ref. [11c]) The IC50 values measured for these ligands in ref. [11c] are collected in Figure SI-4, Supporting Information. B) DC-SIGNR glycomi-
metic ligand binding profile at 150 mgmL@1 DC-SIGNR ECD. Ligands selected for SPR studies are highlighted in blue. C) Left: ligand inhibitory potency towards
DC-SIGN and DC-SIGNR. IC50 values measured in SPR inhibition assays (Man-BSA immobilized on the surface). Right: the structure of the ligands and the IC50
values for DC-SIGN (grey) and DC-SIGNR (blue).
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ty values measured for carbohydrate-protein complexes and
even an influence on the observed binding selectivity of lectins
on the physical format of the assay was noted early on and re-
peatedly confirmed for various systems.[33] Once again, our
data suggest that multiple analytical methods need to be ap-
plied to fully characterize the interaction of lectins with syn-
thetic or natural ligands. This represents an additional element
of complexity for the discovery of selective lectin antagonists.
However it is still possible, using data from various techniques,
to identify ligands of potential interest in drug discovery pro-
grams and to ascertain the structural features that concur to
determine their activity and selectivity. We have obtained here,
for the first time, microarray and SPR data on the recognition
of glycomimetic ligands by DC-SIGNR, which will be the base
for further elaboration of these structures.
Langerin
Langerin is a trimeric CLR abundantly expressed on Langerhans
cells in the epidermis, and at lower levels on CD1c+ myeloid
dendritic cells and lamina propria of the human colon.[34] Apart
from the protective role against HIV mentioned above, the
lectin binds to other pathogens, such as Candida, Saccharomy-
ces, Malassezia furfur, and Mycobacterium leprae.[35] Although
langerin and DC-SIGN share many of their natural ligands, dif-
ferences can be found in their specificity towards fucosylated
glycans. DC-SIGN exhibits a good recognition of many fucose-
based Lewis-type ligands (Lex, Lea, Leb, and Ley), as well as of
the A, B, and H blood group antigens.Langerin binds with
good affinity only the blood group antigens B and A, whereas
Lea, Leb, Ley, and Lex are poorly recognized.[15,36] Moreover, op-
posite to DC-SIGN, langerin selectively recognizes sulfated Gal,
GalNac, and glycosaminoglycans.[5, 11d,15] Additionally, a diver-
gent structural organization and their distinct expression loca-
tions suggest fundamentally different biological roles for these
two CLRs.
In the microarray assay, the signal for trimeric langerin ECD
raised above noise level only for four ligands, three of which
(17.7, 17.14, and 17.15) are known ligands of DC-SIGN
(Figure 4). The corresponding recognition elements 12.7,
12.14, and 12.15 had been previously assessed also against
langerin, using the SPR inhibition experiment described above,
and found to be poor competitors of immobilized Man-BSA.[11c]
SPR inhibition studies were repeated for 12.15 and performed
for the first time with 12.21. Neither of them could inhibit lan-
gerin binding to immobilized Man-BSA, up to millimolar con-
centrations (Supporting Information, Figure SI-5). Some inhibi-
tory activity of 12.15 could be observed in SPR competition
assays, but only when challenging a weaker interaction using a
surface functionalized with Lea-BSA, which is a poor langerin
ligand (Supporting Information, Figure SI-5). This experiment
allowed the evaluation of an IC50 value of 1.8 mm. For 12.21, a
sharp drop in langerin activity could be observed above 1 mm
concentration of the ligand, but the data could not be fitted
to a binding isotherm. The fact that ligands displaying little in-
hibitory activity in the SPR experiment can still light up on the
microarray may depend on the avidity of the polyvalent pre-
sentation generated upon printing them on the chip. However,
we cannot rule out at this stage that these molecules, through
their amide substituents, may be interacting in a noncompeti-
tive fashion, that is, with a different site than the carbohydrate
binding site on the ECD.
Dectin-2
Dendritic cell-associated C-type lectin 2, dectin-2, is a predomi-
nantly macrophage and monocyte associated CLR,[37] with a
known specificity for mannose and a preference for Mana1-
2Man recognition.[16] Dectin-2 binds to bacteria such as Kleb-
siella pneumoniae and Mycobacterium tuberculosis and fungi
such as Candida albicans.[38] Its antifungal activity has been
demonstrated in animal-models.[39] Upon ligand binding,
dectin-2 is able to promote signaling, cytokine secretion, and,
finally, the initiation of a Th17 immune response.[40]
The binding profile of dectin-2 ECD towards the glycomi-
metic library is shown in Figure 5A. It can be observed that
some of the mannosides appear to interact more strongly than
mannose 19.2, a weak binder of dectin-2. Remarkably, dectin-2
exhibits an affinity towards some tertiary amide structures
(17.10, 17.20, 17.30, 17.36, 17.37, 17.38, and 17.39, show-
cased in Figure 5B) and b-fucosylated ligands, which are not or
barely recognized by DC-SIGN (Figure 3A). Although the two
Figure 4. Langerin glycomimetic ligand binding profile at 25 mgmL@1 lectin concentration.
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lectins display a similar profile for mannosides bearing secon-
dary amide structures, they clearly differ in the fucoside section
and more strikingly so in the mannoside-bearing tertiary
amide groups section. This suggests the possibility of an un-
precedented selectivity between the two CLRs towards glyco-
mimetic compounds, which may be related to the different
nature of the two binding sites.[16]
Indeed, the X-ray structure of the dectin-2 in complex with
Man9GlcNAc2 has been recently solved.
[16] Figure 6 shows
dectin-2 CRD superimposed to the X-ray structure of the DC-
SIGN complex with the pseudo-dimannoside 3.[41] The overlay
shows a highly conserved tertiary structure with a difference in
the loops in close proximity of the Ca2+ binding site that con-
tain V351 for DC-SIGN and H171 for dectin-2 (to the right of
the ligand in Figure 6A). At the other side of the Ca2+ ion, the
X-ray structure of dectin-2 shows a very shallow surface, lined
by a Trp side chain (W182, Figure 6A). Alignment of the
dectin-2 and DC-SIGN sites shows that the DC-SIGN binding
region (blue) is more confined, by Phe313 on one side and
Val351 on the opposite side of the Ca2+ ion (Figure 6B). The
Figure 5. Dectin-2 binding profile. Mannosides bearing secondary amide groups are shown as grey bars, mannosides bearing tertiary amide groups are
shown as black bars, fucosides, and controls are shown as white bars. B) Structure of mannose ligands of dectin-2 that do not interact with DC-SIGN.
Figure 6. A) Alignment of DC-SIGN complex with 3 (blue protein, cyan ligand; PDB: 2XR5) and dectin-2 complex of Man9GlcNAc2 (orange protein, ligand not
shown PDB: 5VYB). The Ca2+ ion is shown as a pink sphere. B) Zoom on the Ca2+ binding site viewed from the opposite direction. The curved arrow high-
lights the different orientation of the two loops in the two proteins. The small arrow points to the cyclohexene ring of 3 and to the position of the amide
group in the glycomimetic ligands 12.1–n.
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Val351 side chain is in close contact with the cyclohexane ring
of 3 and near the amide side chains of the amide derivatives
(Figure 6B). In dectin-2, the corresponding loop is more open
and the valine residue is replaced by a histidine in this position
(His171). The different loop orientation, as highlighted in
Figure 6, allows more available space between the protein and
the position of the amide side chain of the mimics (as indicat-
ed by the curved arrow in Figure 6B). As a result, this lectin
may be able to accommodate mannobioside mimics with
larger groups, such as tertiary amides, for the interaction with
its CRD. Further investigation on these ligands is underway.
Conclusions
We have set up and optimized a glycomimetic microarray to
use as a primary screening tool for mannose/fucose selective
C-type lectins. A doubly-functionalized cyclooctyne linker was
used for the fast immobilization of glycomimetic structures
carrying an azide-terminated side chain. The array was validat-
ed with plant or fungal lectins of known specificity and then
interrogated with a set of four human C-type lectins: DC-SIGN,
DC-SIGNR, langerin, and dectin-2. Appropriate controls showed
that, for all the lectins examined so far, the linker does not in-
terfere with the binding process. The glycomimetics used are
based on a central cyclohexane scaffold, carrying either an a-
mannose or a b-fucose residue and further diversified by the
presence of different amide appendages. The mannose based
glycomimetics are structurally derived from the Mana-1–2Man
(mannobioside) natural disaccharide motif. Interestingly, this
disaccharide is a common natural ligand of all the C-type lec-
tins tested in this study, which on the contrary differ strongly
in their ability to interact with fucose-containing oligosacchar-
ides. Thus, screening of mannose and fucose based glycomi-
metics is potentially of high interest in the search for selective
ligands. In fact, only dectin-2 appeared to interact with the b-
fucosides on the array, although less effectively than with most
mannose-based derivatives.
The screening also revealed that the CLRs studied differen-
tially respond to the amide substituents of the mimics, gener-
ating different binding profiles. Whereas langerin was found to
bind weakly to most of the structures examined, DC-SIGN and
DC-SIGNR displayed a rather good tolerance to secondary
amide substituents on the pseudo-mannobioside structure and
some similarity in the recognition profile. Most interestingly, a
set of mannosides carrying tertiary amide substituents were
found to selectively recognize dectin-2 over DC-SIGN, which
may be explained by the known structure of the two lectins’
binding site. Some of the fucose-derived glycomimetics loaded
on the chip also displayed a selectivity for dectin-2 over DC-
SIGN and DC-SIGNR. Thus these screening campaigns simulta-
neously provided the first discovery of glycomimetic ligands
for dectin-2 and gave important indications for the design and
optimization of dectin-2 selective antagonists.
The affinity of selected compounds for DC-SIGN, DC-SIGNR,
and langerin was also measured by SPR inhibition experiments.
The ligand ranking obtained in these solution assays differed
quantitatively from that inferred from array binding profiles. As
often observed in the study of sugar–protein interactions, the
affinity and binding selectivity measured for lectins can strong-
ly depend on the format of the assay, in ways that complicate
the discovery process. In the case at hand, the clustered ligand
presentation on the array can strongly influence the avidity of
the system in ways that cannot be reproduced by binding in-
hibition experiments, where the monovalent ligand in solution
is competing against an immobilized glycoprotein. Thus, the
SPR and array binding data should be regarded as comple-
mentary information, describing different features of the
ligand–lectin interaction. The microarray format of the test we
propose here allows the binding profiles of lectins to be ana-
lyzed even if they are available only in minute quantities, as is
the case for dectin-2 in this study, and may provide structural
information useful in the design of multivalent inhibitors that
mimic the dense ligand presentation of the array surface. Fur-
ther characterization of the binding properties of dectin-2
binders, as well as their structural optimization will be the
object of active investigation in our laboratories.
Experimental Section
General
Chemicals were purchased from Sigma–Aldrich or Acros Organics,
and specific amines from Key Organics, Crea-Chim, Vitas M Labs,
Life Chemicals, Alinda Chemicals, Chem Bridge, or Enamine BB
(suppliers indicated in the Supporting Information, Characterization
of the ligands) and were used without further purification. All reac-
tion solvents were dried over activated 4 or 3 a molecular sieves.
TLC was carried out using 60 F254 TLC plates and visualized by UV
irradiation (254 nm) or by staining with cerium molibdate, potassi-
um permanganate, or ninhydrin solution. Canavalia ensiformis
lectin (ConA) and Aleuria aurantia lectin (AAL) were purchased
from VectorLabs and labeled with Alexa FluorS 555 NHS Ester (Suc-
cinimidyl Ester) (Thermo Fisher Scientific). Human CLRs were pre-
pared and labeled as described below.
Library design
Markush structures were used to search the compound collections
from eMolecules (6585694 compounds, August 2013) and Molport
(10010542, December 2013) for primary and secondary amines. In
particular, only amines with 150,MW,275, number of heavy
atoms 9–20, number of rotatable bonds <6, number of rings >0
and no undefined stereocenters were considered. Amines contain-
ing potentially reactive species[42] and PAINS[43] were also removed.
The resulting compounds were clustered and the cluster center se-
lected (ECFP4 fingerprints as molecular descriptors, maximum dis-
tance between cluster members Tanimoto=0.6). To reduce the
compounds to a number amenable to visual inspection 20% of
the cluster centers was selected maximizing molecular diversity
(based on FCFP4 fingerprints). This resulted in a set of 1116 pri-
mary amines (630 aliphatic and 486 aromatic) and 796 secondary
amines (472 aliphatic and 324 aromatic). After visual inspection
and confirmed commercial availability a set of 38 compounds was
selected for acquisition.
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Synthesis of the ligands
Mannosylated scaffold 11 was prepared according to ref [11c] from
acceptor 9 and the known donor 10. Compound 9, in turn, was
prepared from 8 in two steps, according to ref [11c].
Bis(4-nitrophenyl)-(1S,2S)cyclohex-4-ene-1,2-dicarboxylate
(8)
Diacid 7 (4.23 g, 24.86 mmol, 1 mol equiv) was dissolved in dry
DMF under N2 and pyridine (5.23 mL, 64.63 mmol, 2.6 mol equiv)
was added dropwise to the solution. 4-nitrophenyl trifluoroacetate
(14.03 g, 59.66 mmol, 2.4 mol equiv) was added to the mixture and
the reaction was stirred overnight at 50 8C. After completion (Rf
(product)=0.58 in toluene : EtOAc=8:2+0.1% acetic acid), the re-
action was diluted with dichloromethane (200 mL) and washed
twice with 0.5m HCl (100 mL), twice with cold, saturated NaHCO3
(50 mL) and twice with water (50 mL). The organic phase was dried
over Na2SO4, filtered, and concentrated in vacuo. The obtained
crystals were washed with cooled diethyl ether and filtered to yield
the pure product 8 as a white powder. Yield: 73%; [a]D : +130 (c=
1 in CHCl3 at 20 8C);
1H NMR (400 MHz, CDCl3): d=8.28–8.22 (m,
4H, H10), 7.27–7.22 (m, 4H, H9), 5.83 (app.d, J=2.8 Hz, 2H, H4, H5),
3.27–3.19 (m, 2H, H1, H2), 2.78–2.68 (m, 2H, H3ps-eq, H6ps-eq), 2.48–
2.37 ppm (m, 2H, H3ps-ax, H6ps-ax) ;
13C NMR (100 MHz, CDCl3): d=
172.8 (C7) ; 155.4 (C11) ; 145.7 (C8) ; 125.5 (C10) ; 124.9 (C5, C4) ; 122.5
(C9) ; 41.5 (C1, C2) ; 28.0 ppm (C3, C6) ; MS (ESI): m/z : calcd for
[C20H16N2O8Na]
+ : 435.08 [M+Na]+ ; found: 435.33; m.p. 171 8C.
2,3,4-Tri-O-benzoyl-a-l-fucopyranosyl-1-trichloroacetoimi-
date 13
l-(@)-Fucose (200 mg, 1.22 mmol, 1 mol equiv) was dissolved at
@40 8C in pyridine (1 mL) under a N2 atmosphere and benzoyl chlo-
ride (636 mL, 5.48 mmol, 4.5 mol equiv) was added dropwise to the
solution. After 2 h, the starting unprotected sugar was not detect-
ed by TLC anymore (Rf=0.1 in toluene : EtOAc=9:1), so the reac-
tion was left to warm to room temperature and stirred until there
was only one major spot visible on the TLC plate (Rf=0.24 in tolu-
ene/EtOAc=97:3). Upon completion, the reaction mixture was di-
luted with water and extracted with CH2Cl2. The joint organic
phases were dried over Na2SO4, filtered, and concentrated in
vacuo, to yield the product 1,2,3,4-tetra-O-benzoyl-l-fucopyranose
as a white foam. Yield: quant. (a/b=9:1). Under these conditions,
only a small amount of fuco-furanose form is obtained, typically
around 1% by 1H NMR, so that no additional purification is needed
before the next step. 1H NMR (400 MHz, CDCl3): a-anomer: d=
8.17–7.21 (m, 20H, OBz), 6.87 (d, 1H, H1, J1-2=3.7 Hz), 6.08 (dd, 1H,
H3, J3-4=3.2, J3-2=10.8 Hz), 5.99 (dd, 1H, H2, J2-3=10.8, J2-1=3.7 Hz),
5.90 (dd, 1H, H4, J4-5=1.1, J4-3=3.2 Hz), 4.64 (dd, 1H, H5, J5-6=6.6,
J=12.9 Hz), 1.32 (d, 3H, H6, J=6.4 Hz); b-anomer: d=8.17–7.21
(m, 20H, OBz), 6.21 (d, 1H, H1, J1-2=8.3 Hz), 6.06 (m, 1H, H2), 5.81
(dd, 1H, H4, J4-5=1.0, J4-3=3.4 Hz), 5.72 (m, 1H, H3), 4.34 (dd, 1H,
H5, J5-6=5.7, J=12.5 Hz), 1.39 (d, 3H, H6, J=6.4 Hz); MS (ESI): m/z :
calcd for [C34H28O9Na]
+ [M+Na+]: 603.16; found: 603.35.
1,2,3,4-Tetra-O-benzoyl-l-fucopyranose (707.3 mg, 1.218 mmol,
1 mol equiv) was dissolved in dry THF and cooled to 0 8C under a
N2 atmosphere. 2m MeNH2 in THF (731 mL, 1.462 mmol, 1.2 mol
equiv) was added dropwise to the solution. After 1 h, the major
spot on the TLC had a slightly lower Rf than the starting material
and a new spot started to appear further below. The solution was
concentrated in vacuo, and the product was purified by flash chro-
matography (Rf=0.18 and 0.15 for a and b anomers in toluene/
EtOAc=9:1) to yield pure 2,3,4-tri-O-benzoyl-l-fucopyranose as a
colourless oil. Yield: 74% (a/b=2:1); 1H NMR (400 MHz, CDCl3): a-
anomer: d=8.18–7.23 (m, 15H, OBz), 6.04 (dd, 1H, H3, J3-2=10.7,
J3-4=3.2 Hz), 5.81–5.77 (m, 2H, H1, H4), 5.68 (m, 1H, H2), 4.69 (dd,
1H; H5, J5-6=6.5, J5-4=13.1 Hz), 1.30 (d, 3H, H6, J6-5=6.5 Hz); b-
anomer: d=8.18–7.23 (m, 15H, OBz), 5.73 (dd, 1H, H4, J4-5=1.0,
J3-4=3.5 Hz), 5.71–5.66 (m, 1H, H3), 5.58 (dd, 1H, H2, J2-1=7.9, J2-3=
10.4 Hz), 4.99 (d, 1H, H1, J1-2=7.9 Hz), 4.13 (dd, 1H, H5, J5-6=6.1,
J5-4=12.8 Hz), 1.39 ppm (d, 3H, H6, J6-5=6.5 Hz); MS (ESI): m/z : cal-
culated for [C27H24O8Na]
+ [M+Na+]: 499.14; found: 499.84
2,3,4-Tri-O-benzoyl-l-fucopyranose (460 mg, 0.969 mmol, 1 mol
equiv) was dissolved in dry dichloromethane (5 mL) and cooled to
0 8C. DBU (58 mL, 0.388 mmol, 0.4 mol equiv) and trichloroacetoni-
trile (972 mL, 9.694 mmol, 10 mol equiv) were added to the solution
which was left to warm to room temperature and stirred until the
starting material had disappeared. The solution was concentrated
in vacuo, and the product was purified by flash chromatography
(Rf=0.34 in hexane/EtOAc=9:1) to yield the pure product as a col-
ourless oil (only a-anomer). Yield: 93%; 1H NMR (400 MHz, CDCl3):
d=8.60 (s, 1H, NH), 8.18–7.25 (m, 15H, OBz), 6.83 (d, 1H, H1, J1-2=
3.5 Hz), 6.04 (dd, 1H, H3, J3-2=10.9, J3-4=3.5 Hz), 5.91 (dd, 1H, H2,
J2-3=10.9, J2-1=3.5 Hz), 5.89–5.86 (m, 1H, H4), 4.65 (dd, 1H, H5,
J5-6=6.5, J5-4=6.3 Hz), 1.30 ppm (d, 3H, H6, J6-5=6.5 Hz); MS (ESI):
m/z : calcd for [C29H24O8ClNa]
+ [M+Na+]: 642.05; found: 642.37.
1,2-Cyclohexanedicarboxylic acid, (1S,2S,4S,5S)-4-(2-azido-
ethoxy)-5-[(2,3,4-tri-O-benzoyl-b-d-fucopyranosyl)oxy]-1,2-
bis(p-nitrophenylester) (14)
A mixture of acceptor 9 (250 mg, 0.4013 mmol, 1 mol equiv) and
donor 13 (207 mg, 0.4013 mmol, 1 mol equiv) was co-evaporated
from toluene three times. Powdered and activated 4 a molecular
sieves (acid washed) were added and the mixture was kept under
vacuum for a few hours and then dissolved in dry CH2Cl2 (4 mL).
The solution was cooled to @30 8C and TMSOTf (9 mL,
0.0401 mmol, 0.2 mol equiv) was added to the mixture. The reac-
tion was stirred at @30 8C for 2 h and at RT for an additional 1.5 h
and was then quenched with Et3N. The mixture was filtered over a
Celite pad. The solution was concentrated in vacuo, and the prod-
uct was purified by flash chromatography (Rf=0.22 in hexane/
EtOAc=6:4) to yield the pure product 14 as a colorless foam.
Yield: 72%; 1H NMR (400 MHz, CDCl3): d=8.23–6.83 (m, 23H, HAr),
5.75–5.63 (m, 2H, H2, H4), 5.57 (dd, 1H, H3, J3-2=10.5, J3-4=3.4 Hz),
4.86 (d, 1H, H1, J1-2=8.0 Hz), 4.14 (m, 1H, C2), 4.06 (q, 1H, H5, J5-4=
12.9, J5-6=6.3 Hz), 3.87 (m, 1H, C1), 3.84–3.77 (m, 1H, H7a), 3.69–
3.62 (m, 1H, H7b), 3.41–3.31 (m, 2H, H8a,b), 3.22–3.13 (m, 1H, C4),
3.02–2.92 (m, 1H, H5), 2.36–2.27 (m, 1H, C3 or 6eq), 2.21–2.12 (m, 1H,
H3 or 6 eq), 2.08–1.90 ppm (m, 2H, H3ax, 6ax) ;
13C NMR (100 MHz, CDCl3):
d=172.5, 172.3 (C9) ; 166.3, 165.9, 165.7 (COBz) ; 155.5, 155.3 (C10) ;
145.8, 145.7 (C13) ; 133.9, 133.7, 133.5 (CHBz) ; 130.3, 130.0, 130.0
(CHBz) ; 129.5, 129.1 (CquatBz) ; 128.9, 128.7, 128.6 (CHBz) ; 125.5, 125.4
(C12) ; 122.7, 122.6 (C11) ; 100.2 (C1) ; 75.0 (CC1) ; 72.7 (CC2) ; 72.0 (C3) ;
71.3 (C2) ; 70.4 (C5) ; 70.1 (C4) ; 69.6, 68.7 (C4) ; 51.2 (C8) ; 39.0, 39.0
(CC4,CC5) ; 27.5, 27.2 (CC3, CC6) ; 16.9, 16.7 ppm (C6) ; MS (ESI): m/z :
calcd for [C49H43N5O17]
+ : 996.26; found: 996.86.
General procedure for the synthesis of bisamides 12 and 15
Amine coupling : Scaffold 11 or 14 (1 mol equiv) was dissolved in
dry THF or DMF see the Supporting Information) under N2 and the
amine (3 mol equiv) was added to the solution. For amines sold as
ammonium salts and amines with low reactivity (see the Support-
ing Information) 3 mol equiv of Et3N were also added. The mixture
was stirred at RT from 1 h to 2 days, and monitored by TLC or
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NMR. Upon completion, the solution was washed with 1m HCl, 1m
NaOH and water on supported liquid extraction cartridges (Biotage
ISOLUTES HM-N). The crude was purified by flash chromatography
(CH2Cl2 with gradient of methanol from 0 to 20%) or used without
purification in the following Zempl8n-deprotection if the purity
was satisfying.
Zempl8n debenzoylation : The benzoyl-protected bisamide (1 mol
equiv) was dissolved in distilled MeOH and 1m freshly prepared
NaOMe in MeOH was added to the solution (1.5 mol equiv
NaOMe) to a 0.1m final concentration of the substrate. After com-
pletion, the reaction was neutralized with AmberliteS IR120 hydro-
gen form ion-exchange resin, filtered, and concentrated in vacuo.
The crude was purified by direct or reverse-phase flash cromatog-
raphy, yielding the pure product 12 or 15.
Library characterization : Ligands 12.1, 12.3, 12.4, 12.7, 12.12,
12.14, 12.15, 12.18, and 12.19 were previously described by Varga
et al. ;[11c] ligand 12.2 was described by Reina et al. ,[44] whereas the
characterization of the other ligands is detailed in the Supporting
Information.
Conjugation of the ligands with the bifunctional linker 16
A 10 mm solution of the ligands was prepared in water and when
necessary for complete solubilization, 5% DMSO (Thermo Scientific
Molecular ProbesQ) was added. The compounds were stirred over-
night at room temperature with equimolar amounts of 16 (N-
[(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethyloxycarbonyl]-1,8-diami-
no-3,6-dioxaoctane, BCN-amine, Sigma Aldrich) in water and the
conversion of the SPAAC-reactions was monitored by MALDI-TOF
mass spectrometry by using 2,5-dihydroxybenzoic acid (DHB) as a
matrix (5 mgmL@1 in CH3CN/0.1% aqueous TFA, 3:7 containing
0.005% NaCl). The MALDI data are reported in the Supporting In-
formation.
Ligand printing and screening
Stock solutions of the conjugates 1 mm in water were diluted with
sodium phosphate buffer (300 mm, pH 8.5, 0.005% TweenS 20,
10% DMSO) to a final concentration of 50 mm. 40 mL of each solu-
tion was placed into a 384 well source plate (Scienion, Berlin, Ger-
many), which was stored at @20 8C and reused if necessary. These
solutions (750 pL, 3 drops of 250 pL) were spotted onto NHS-func-
tionalized glass slides (NexterionS Slide H–Schott AG, Mainz, Ger-
many). Ligands were spotted in 4 replicates (9 different ligands per
row), establishing the complete microarray that was printed in
7 copies onto each slide After printing, the slides were placed in a
75% humidity chamber (saturated NaCl solution) at room tempera-
ture overnight. The unreacted NHS groups were quenched by plac-
ing the slides in a 50 mm solution of ethanolamine in sodium
borate buffer 50 mm, pH 9.0, for 1 h.
The immobilized ligands were probed with solutions of fluores-
cently labeled (Alexafluor555) plant and fungal lectins. Solutions of
Concanavalin A (ConA-555, 1 mgmL@1) and Aleuria aurantia lectin
(AAL-555, 15 mgmL@1) were prepared in PBS containing 2 mm
CaCl2, 2 mm MgCl2, and 0.005% Tween-20. For incubations, 200 mL
of the lectin solution was applied to each microarray by using
8 Well ProPlateQ Slide Module incubation chambers for 1 h in the
dark at room temperature. The slides were washed under standard
conditions (PBS and water), dried with argon, and the introduced
fluorescence was analyzed with a microarray scanner.
The immobilized ligands were probed with solutions of fluores-
cently labeled C-type lectins. Solutions of Cy3-labelled DC-SIGN
ECD-Cy3 (50 mgmL@1, DOL: 0.3) and DC-SIGNR ECD (150 mgmL@1,
DOL: 0.95), langerin-Cy3 (25 mgmL@1, DOL: 0.7) and dectin-2-Cy3
(50 mgmL@1, DOL: 0.4) were diluted in TBS (50 mm Tris·HCl, 150 mm
NaCl, pH 8.0) containing 4 mm CaCl2, 0.5% BSA and 0.005%
TweenS 20. For incubations, 200 mL of each lectin solution was ap-
plied to each subarray by using 8 Well ProPlate Module incubation
chambers. The microarray was incubated by gentle shaking over-
night in the dark at 4 8C. The slides were washed using TBS con-
taining 4 mm CaCl2 and water, dried with argon, and the fluores-
cence was analyzed with a microarray scanner.
Expression and purification of CLRs
DC-SIGN extracellular domain (DC-SIGN ECD) and langerin extracel-
lular domain (langerin ECD) constructs were produced and purified
as previously described.[3a,24]
DC-SIGNR ECD and dectin-2 ECD were expressed in E. coli
BL21(DE3) in 1 L of LB medium supplemented with 50 mgmL@1 ka-
namycin at 37 8C. Expression was induced by addition of 1 mm iso-
propyl 1-thio-d-galactopyranoside (IPTG) when the culture had
reached an A600 nm of 0.8 and was maintained for 3 h. The protein
was expressed in the cytoplasm as inclusion bodies. Cells were har-
vested by a 20 min centrifugation at 5000 g at 4 8C. The pellet was
re-suspended in 30 mL of a solution containing 150 mm NaCl,
25 mm Tris-HCl, pH 8 and one antiprotease mixture tablet (Com-
plete EDTA free, Roche). Cells were disrupted by sonication and
cell debris eliminated by centrifugation at 100000 g for 45 min at
4 8C in a Beckman 45Ti rotor. The pellet was solubilized in 30 mL of
6m guanidine-HCl containing 25 mm Tris-HCl pH 8, 150 mm NaCl
and 0.01% b-mercaptoethanol. The mixture was centrifuged at
100000 g for 45 min at 4 8C and the supernatant was diluted 5-
fold, by slow addition with stirring, with 1.25m NaCl, 25 mm CaCl2,
and 25 or 200 mm Tris-HCl pH 8 for DC-SIGNR and dectin-2 ECD,
respectively. The diluted mixture was dialyzed against ten volumes
of 25 mm Tris-HCl, pH 8, 150 mm NaCl, 4 mm CaCl2 (buffer A) with
three buffer changes. After dialysis, insoluble precipitate was re-
moved by centrifugation at 100000 g for 1 h at 4 8C. The superna-
tant containing DC-SIGNR ECD was loaded on Mannan agarose
column (Sigma) for purification by affinity chromatography equili-
brated with buffer A. After loading, DC-SIGNR ECD was tightly
bound to the column and eluted in the same buffer without CaCl2
but supplemented with 1 mm EDTA (buffer B). This step was fol-
lowed by SEC (size exclusion chromatography) by using a Super-
ose 6 column (GE Heathcare) equilibrated with buffer A. Fractions
were analyzed by SDS-PAGE (12%) and DC-SIGNR ECD containing
fractions were pooled and concentrated by ultrafiltration (YM10
membrane from Amicon). The supernatant containing the Strep
tagged dectin-2 ECD was loaded onto a StrepTrap HP column (GE
Heathcare) at 4 8C. Unbound proteins were washed away with buf-
fer A before dectin-2 ECD was eluted with buffer C (150 mm NaCl,
25 mm Tris-HCl, pH 8, 4 mm CaCl2, 2.5 mm d-desthiobiotin). Eluted
fractions were analyzed by SDS-PAGE (15%) and dectin-2 ECD-con-
taining fractions were pooled and concentrated by ultrafiltration
(YM10 membrane from Amicon).
Each protein construct was checked by N-terminal amino acid se-
quencing and mass spectrometry.
The labeling procedure is described in the Supporting Information.
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